JUST PUBLISHED: Audrey Kuhn's Poetic Journey Through Love, Loss, and Resilience Amid Alzheimer's and Pandemic Struggles
God's Voice Through the Despair
Charleston, SC, Aug. 13, 2025 (GLOBE NEWSWIRE) -- God's Voice Through the Despair, authored by Audrey L. Kuhn, unveils a deeply personal journey through love, loss, and faith amid the trials of Alzheimer's, a global pandemic, and the challenges of caregiving. Audrey's narrative captures her experience as a devoted caregiver for her husband, who faces the devastating effects of Alzheimer's. Over 260 days of separation due to pandemic restrictions test her resilience, forcing her to confront the emotional weight of watching her beloved partner gradually fade away. In her darkest moments, Audrey finds solace through poetry, beginning with the poignant piece 'Little Tears,' which ignites a cascade of reflections that articulate her innermost feelings of sorrow and hope. Audrey L. Kuhn's verses explore intricate themes of love, loss, and the search for meaning amid chaos. Each poem serves as a testament to her strength, revealing the beauty of nature and the spiritual lessons learned through adversity. Her words resonate with the struggles of caregiving, encapsulating vulnerability and the courage needed to face each day. As she navigates the complexities of her husband's illness, Audrey's unwavering faith becomes her guiding light, offering comfort not only to herself but also to others grappling with similar challenges. God's Voice Through the Despair culminates in a heartfelt farewell, a final expression of love that transcends the pain of separation. This collection stands as a beacon of hope for anyone enduring the trials of caregiving, loss, and the quest for divine guidance. Audrey L. Kuhn invites readers to embrace their own narratives, reminding them that even in the darkest moments, they are never truly alone. Her journey serves as a source of comfort and inspiration, affirming the indomitable power of resilience, love, and faith. God's Voice Through the Despair is available for purchase online at Amazon.com and BarnesandNoble.com. About the Author: Audrey L. Kuhn, a native of Lancaster County, Pennsylvania, is the fifth of seven children from a conservative, faith-rooted family. Her writings reflect her resilient character and compassionate spirit. Inspired by the beauty of creation, her poetry explores themes of life, death, and beyond. Many of her poems have been shared at church gatherings, funerals, and in collaborative works like Poems and Harp for the Soul. Known for her heartfelt verses, Audrey's work offers comfort to those experiencing grief or loss. Her book, God's Voice Through the Despair, showcases her enduring faith and spiritual insight.
Media Contact: poemsbyaudrey@outlook.com
Available for interviews: Author, Audrey L. Kuhn
Attachment
God's Voice Through the Despair
CONTACT: Leah Joseph Palmetto Publishing publicity@palmettopublishing.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
20 minutes ago
- New York Post
I'm a doctor — the habit I have after every meal because I'm terrified of having a heart attack or dementia
Read carefully — and don't lose the thread. A super speedy habit you're probably skipping could reduce your changes of heart attack, stroke and dementia. But a naturopathic doctor who goes by Dr. Mac says she does it multiple times a day — and the science backs her up. Advertisement Dr. Mac says she flosses after every meal to reduce her heart attack and dementia risk. Tiktok/@drtoohey 'If you see me flossing after every meal, it's because I am terrified of having a heart attack and terrified of getting dementia when I'm older,' she said in a viral TikTok video (@drtoohey) with nearly 70,000 views. Though the American Dental Association recommends flossing at least once a day, only about 32% say they do. In the same 2019 study, nearly 32% of Americans admitted they don't floss at all. Good oral hygiene has been tied to a bunch of health benefits, and not just for your mouth. That because the bacteria that causes gingivitis, or gum disease, doesn't just stay around your teeth. Advertisement In 2019, researchers in Norway found DNA evidence that 'bacteria causing gingivitis can move from the mouth to the brain,' said Piotr Mydel of Broegelmanns Research Laboratory at the University of Bergen (UiB). There, it makes a protein that destroys brain cells, which can lead to memory loss and dementia. In their study of 53 perople with Alzheimer's, 96% of them tested positive for this enzyme. 'The public needs to be more aware of the correlation between oral health and cognitive abilities,' Chia-Shu Lin, a professor in dentistry at National Yang Ming Chiao Tung University in Taiwan, previously told Newsweek. Advertisement Oral hygiene has been linked to lots of health conditions. Mapodile M./ – Oral hygiene issues can also increase your odds of developing heart disease. It's no small difference, either: People with gum disease are 28% more likely to suffer a heart attack. 'Studies show that people who brush their teeth regularly, along with getting dental cleanings, tend to have healthier hearts and a lower risk of heart disease,' gastroenterologist Dr. Saurabh Sethi said in one viral TikTok. Advertisement Your stroke risk is also influenced by your brushing and flossing habits. One study piblished this year linked flossing teeth at least once a week to a 22% lower risk of ischemic stroke, 44% lower risk of cardioembolic stroke and 12% lower risk of AFib. 'Oral health behaviors are linked to inflammation and artery hardening,' said the study's lead author, Dr. Souvik Sen. 'Flossing may reduce stroke risk by lowering oral infections and inflammation and encouraging other healthy habits. 'Many people have expressed that dental care is costly,' he continued. 'Flossing is a healthy habit that is easy to adopt, affordable and accessible everywhere.' That's not all: Recent research has linked oral bacteria to head and neck cancers as well. Though Dr. Mac admitted that it might seem 'crazy' that flossing could have such an enormous health impact, she also said it 'makes sense because everything's so connected.' 'But you best believe if you invite me out to a restaurant, I will be flossing after that meal. Respectfully, I will walk away and go to the bathroom or step outside, but I am getting in there. Because those are two ways I'm not gonna go,' she said.
Yahoo
5 hours ago
- Yahoo
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the 'Company' or 'VivoSim Labs'), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer. Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players. At VivoSim Labs, he will lead go-to-market strategy, partnerships, and the expansion of the Company's San Diego-based services that combine organ-specific 3D models with AI-driven analytics to deliver decision-ready insights earlier in development. Market Opportunity: According to an internal analysis conducted by VivoSim Labs in July 2025, the global combined liver and gastrointestinal in-vitro models and toxicology services market generated $641M in revenue in 2024. Services represented 53.1% of revenue vs. models at 46.9% of revenue. The United States accounted for $325M (50.8%) of the global market for liver toxicology models and services. Adoption of 3D human-relevant systems is rising, with the global in vitro liver model market growing at 5.9% CAGR from 2020 to 2024. Category Tailwinds: Biopharma sponsors are accelerating the use of non-animal new approach methodologies (NAMs). Regulatory momentum, including the FDA Modernization Act 2.0 (2022), supports validated alternatives and is catalyzing broader adoption of human-relevant in vitro models for ADME and toxicology. How AI Helps: VivoSim Labs applies AI to quantify multi-parametric toxicity signatures across liver and intestinal organoid assays. By improving signal-to-noise in dose-response analyses, the platform helps project teams prioritize candidates and plan studies with greater confidence. 'VivoSim Labs sits at the intersection of biology and AI. Our NAMkind™ models are designed to answer make-or-break questions earlier,' said Tony Lialin, Chief Commercial Officer, VivoSim Labs. 'We will scale a high-touch, consultative service from our San Diego lab so pharma and biopharma teams get decision-ready toxicology insights that aim to streamline pre-IND decision-making and reduce late-stage surprises.' 'Tony has a rare track record of turning disruptive science into durable commercial engines,' said Keith Murphy, Executive Chairman, VivoSim Labs. 'As sponsors move rapidly to 3D, human-relevant models, they want a partner—not just a plate or a protocol—to guide critical decisions. Tony knows how to build the solutions that our customers need.' About VivoSim Labs VivoSim Labs, Inc. ("VivoSim" and the 'Company'), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies ("NAM") models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration ('FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit Forward-Looking Statements Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding expansion of the Company's San Diego-based services; the potential for the Company's organ-specific 3D models and AI-driven analytics to deliver decision-ready insights earlier in development; the market opportunity and market size of gastrointestinal in-vitro models and toxicology services; and the ability of the Company's services to improve signal-to-noise in dose-response calls or help project teams prioritize candidates and studies with greater confidence. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. ContactInvestor Relationsinfo@ Labs, in to access your portfolio
Yahoo
5 hours ago
- Yahoo
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025
Breakthrough Epigenetic Modulator LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the epigenetic modulation of key cellular pathways. 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and DNA damage response. By inhibiting PP2A, LB-100 sensitizes tumors to DNA-damaging agents, including chemotherapy, radiation, and immunotherapy, LIXTE is targeting high-unmet needs in the $200 billion global oncology market (Grand View Research, 2025 projection). Potential upcoming catalysts in 2025, including multiple trial results, position LIXTE as a potential disruptor in resistant cancers, where traditional treatments fail due to limited efficacy and toxicity. Upcoming Catalysts: Anticipated Trial Results in 2H 2025 1B/2 Trial – Ovarian Clear Cell Carcinoma (OCCC) Ovarian clear cell carcinoma is an aggressive and chemoresistant subtype of epithelial ovarian cancer, accounting for ~5–10% of all ovarian malignancies but disproportionately contributing to ovarian cancer mortality. The Phase 1B/2 study of LB-100 in combination with carboplatin and paclitaxel is designed to overcome platinum resistance by leveraging LB-100's synergistic enhancement of DNA damage and impaired repair in tumor cells. Status: Enrolled, with interim safety completed Upcoming Milestone: Preliminary efficacy data expected Q4 2025 Potential Market Impact: Global OCCC treatment market is projected to exceed $750 million by 2028 due to rising incidence and limited targeted therapies 1B/2 Trial – Advanced Soft Tissue Sarcoma (STS) Soft tissue sarcomas are a diverse and difficult-to-treat group of cancers arising from connective tissues. For patients with advanced or metastatic disease, prognosis remains poor. LIXTE's Phase 1B/2 study evaluates LB-100 in combination with doxorubicin, the current standard of care, in patients with advanced STS. Status: Ongoing dose escalation, with expansion cohort enrollment underway Upcoming Milestone: Progression-free survival (PFS) and objective response rate (ORR) update late Q3 2025 Potential Market Impact: The global STS drug market is estimated to reach $2.1 billion by 2030, driven by the emergence of combination therapies and unmet medical need 1B Trial – Metastatic Microsatellite Stable (MSS) Colon Cancer MSS colon cancer, representing roughly 85% of metastatic colorectal cancer (mCRC), remains unresponsive to checkpoint inhibitors. LIXTE is conducting a Phase 1B trial assessing the safety and activity of LB-100 in combination with immune checkpoint blockade and chemotherapy, seeking to overcome immune resistance in this cold tumor type. Status: Actively recruiting Upcoming Milestone: Initial biomarker and response data anticipated in Q4 2025 Potential Market Impact: The global colorectal cancer therapeutics market is expected to surpass $18 billion by 2030, with MSS disease representing the majority of treatment-resistant cases Platform Potential and Market Opportunity LIXTE's strategy of targeting PP2A to potentiate multiple treatment modalities positions LB-100 as a versatile combination agent with broad applicability across solid tumors. The platform's potential spans oncology subtypes with high unmet need, limited innovation, and growing incidence. Strong IP Position: Multiple issued and pending patents covering composition, methods of use, and combinations Pipeline Expansion: Additional tumor types and investigator-sponsored studies are under review, including glioblastoma, pancreatic, and lung cancers Partnership Potential: Ongoing discussions with academic institutions and biopharma partners for co-development opportunities Contact sales@ for Analyst Report coverage and other investor/public relations services. About LIXTE Biotechnology Holdings, Inc. LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. More information can be found at: 24/7 MARKET NEWS, INC DisclaimerPlease go to for further LIXT information and LIXT disclosure information. CONTACT:24/7 Market NewsEditor@ Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, the popularity and/or competitive success of the Company's acquired football and other sports teams, the Company's ability to attract players and staff for acquired clubs, unsuccessful acquisitions or other strategic transactions, the possibility of a decline in the popularity of football or other sports, the Company's ability to expand its fanbase, sponsors and commercial partners, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
